BAY 43-9006
| Code | Size | Price |
|---|
| AG-CR1-0025-M001 | 1 mg | £25.00 |
Quantity:
| AG-CR1-0025-M005 | 5 mg | £50.00 |
Quantity:
| AG-CR1-0025-M025 | 25 mg | £120.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
Ambient
Storage:
4°C
Documents
Further Information
Alternate Names/Synonyms:
Sorafenib; N-[4-Chloro-3-(trifluoromethyl)phenyl]-([4-[2-(N-methylcarbamoyl)(4-pyridyloxy)]phenyl]amino)-carboxamide
Appearance:
White to off-white solid.
CAS:
284461-73-0
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS07
Hazards:
H302, H315, H319
InChi:
InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)
InChiKey:
MLDQJTXFUGDVEO-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 284461-73-0. Formula: C21H16ClF3N4O3. MW: 464.8. Antitumor compound. Broad-spectrum kinase inhibitor. Raf kinase inhibitor. Apoptosis inducer. Cytostatic. Angiogenesis inhibitor. Review.
MDL:
MFCD06411450
Molecular Formula:
C21H16ClF3N4O3
Molecular Weight:
464.8
Package Type:
Vial
Precautions:
P261, P270, P280, P301, P312
Product Description:
Antitumor compound [1]. Broad-spectrum kinase inhibitor [2]. Raf kinase inhibitor [2, 3]. Apoptosis inducer [3, 4]. Cytostatic [5]. Angiogenesis inhibitor [2, 5]. Review [6].
Purity:
>98% (HPLC)
Signal word:
Warning
SMILES:
CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=C1
Solubility Chemicals:
Soluble in DMSO, 100% ethanol, methanol or ethyl acetate.
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
BAY 43-9006: preclinical data: S. Wilhelm & D.S. Chien; Curr. Pharm. Des. 8, 2255 (2002) | Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature: L. Adnane, et al.; Meth. Enzymol. 407, 597 (2005) | The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells: D.J. Panka, et al.; Cancer Res. 66, 1611 (2006) | The kinase inhibitor Sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress: M. Rahmani, et al.; Mol. Cell. Biol. 27, 5499 (2007) | BAY-43-9006 Bayer/Onyx: J.T. Lee & J.A. McCubrey; Curr. Opin. Investig. Drugs 4, 757 (2003) | Sorafenib (BAY 43-9006): review of clinical development: R. Ng & E.X. Chen; Curr. Clin. Pharmacol. 1, 223 (2006)